Drug Trial Radar · NCT07057765
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 5, 2025
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Ain Shams UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Markers of Inflammation
Interventions
Observational Assessment of Standard R-CHOP TreatmentDrug
Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Following 3 Cycles of R-CHOP Based on Baseline Inflammatory MarkersTime frame: Baseline (Day 1 of Cycle 1) and Day 63 (End of Cycle 3; each cycle is 21 days)
- Incidence of Treatment-Related Toxicity During Initial Treatment According to Baseline Inflammatory MarkersTime frame: Day 1 of Cycle 1 through Day 63 (End of Cycle 3; each cycle is 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University
Cairo, Cairo Governorate, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.